Last month, the Center for Medicare and Medicaid Services released this statement:
In August 2022, President Biden signed the Inflation Reduction Act of 2022 into law. The law improves Medicare by expanding benefits, lowering drug costs, and improving the sustainability of the Medicare program for generations to come.
The law provides meaningful financial relief for millions of people with Medicare by improving access to affordable treatments and strengthening Medicare, both now and in the long run. For the first time, the law provides Medicare the ability to directly negotiate the prices of certain high-expenditure, single-source drugs without generic or biosimilar competition.
The Centers for Medicare & Medicaid Services (CMS) selected ten drugs covered under Medicare Part D for the first cycle of negotiations for initial price applicability year 2026. They engaged in voluntary negotiations with the drug companies for the selected drugs. Below is the list of negotiated prices, which the statute refers to as Maximum Fair Prices (MFPs), for ten drugs covered under Medicare Part D that will go into effect beginning January 1, 2026, based on negotiations and agreements between CMS and participating drug companies.
The following drugs are included:
Drug Name List price (monthly) Negotiated price (monthly)
Januvia $527.00 $113.00
Fiasp $495.00 $119.00
Farxiga $556.00 $178.50
Enbrel $7,106.00 $2,355.00
Jardiance $573.00 $197.00
Stelara $13,836.00 $4, 695.00
Xarelto $517.00 $197.00
Eliquis $521.00 $231.00
Entresto $628.00 $295.00
Imbruvica $14,934.00 $9,319.00
These prices will go into effect on January 1, 2026.
